J.M. Sánchez-Torres
Hospital Universitario de La Princesa(ES)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Diagnosis and Treatment, Lung Cancer Research Studies, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Brain metastases from lung cancer responding to erlotinib: the importance ofEGFRmutation(2010)317 cited
- → Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients(2019)257 cited
- → A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial(2021)114 cited
- → Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping(2018)85 cited
- → Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer(2014)65 cited
- → A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy(2020)56 cited
- → BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.(2013)54 cited
- → Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden(2022)46 cited
- → Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine(2010)45 cited
- → Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies(2020)35 cited